Regulatory adverse drug reaction analyses support a temporal increase in psychiatric reactions after initiation of cystic fibrosis combination modulator therapies
Journal of Cystic Fibrosis · 2025
DOI: 10.1016/j.jcf.2024.09.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2025. Verfasst von Jacob O'Connor und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK. Hauptthemen laut MEDLINE: Cystic Fibrosis, Mental Disorders, Adverse Drug Reaction Reporting Systems, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
INTRODUCTION: Despite improved outcomes for many people with cystic fibrosis, there have been reports of adverse neuropsychiatric effects of modulator therapy. The aim of this research is to define temporal associations in adverse drug reaction (ADR) reports for available CFTR modulators. METHODS: Methods include an analysis of the UK Yellow Card Scheme data for ADRs through accessing interactive Drug Analysis Profiles (iDAPs) to define temporal trends in absolute and proportional counts. RESULTS: Since the introduction of ETI, there has been an increase in the absolute number of psychiatric ADRs reported as well as a statistically significant increase in the proportion of psychiatric ADRs in the pre-ETI and post-ETI periods. CONCLUSION: In the post-ETI period, psychiatric ADRs are the most prevalent ADR reported via the Yellow Card scheme. Despite an unclear mechanism, there is significant clinical relevance in counselling and monitoring regarding psychiatric effects of CFTR modulator therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK.
- Adult Cystic Fibrosis Centre, Liverpool Heart & Chest Hospital NHS Foundation Trust, Liverpool, UK; Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.
- Department of Women's and Children's Health, Institute in the Park, Alder Hey Children's Hospital, University of Liverpool, Liverpool, UK.
- Liverpool Centre for Cardiovascular Sciences, Liverpool Heart & Chest Hospital NHS Foundation Trust and University of Liverpool, Liverpool, UK. Electronic address: F.Frost@liverpool.ac.uk.
Zitieren
APA
O'Connor, J., Nazareth, D., Wat, D., Southern, K. W., & Frost, F. (2025). Regulatory adverse drug reaction analyses support a temporal increase in psychiatric reactions after initiation of cystic fibrosis combination modulator therapies. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2024.09.010
Vancouver
O'Connor J, Nazareth D, Wat D, Southern KW, Frost F. Regulatory adverse drug reaction analyses support a temporal increase in psychiatric reactions after initiation of cystic fibrosis combination modulator therapies. Journal of Cystic Fibrosis. 2025. doi:10.1016/j.jcf.2024.09.010
BibTeX
@article{OConnor2025,
author = {O'Connor, Jacob and Nazareth, Dilip and Wat, Dennis and Southern, Kevin W and Frost, Freddy},
title = {Regulatory adverse drug reaction analyses support a temporal increase in psychiatric reactions after initiation of cystic fibrosis combination modulator therapies},
journal = {Journal of Cystic Fibrosis},
year = {2025},
doi = {10.1016/j.jcf.2024.09.010}
}
EUVIMED